You have 0 free articles left this month.

Lawyers Weekly - legal news for Australian lawyers

Powered by MOMENTUM MEDIA
lawyers weekly logo
Advertisement
NewLaw

Slaters probe pharmaceutical giant's conduct

Slater & Gordon has announced it is conducting a detailed investigation into shock disclosures made by Australian company Sigma Pharmaceuticals which resulted in a massive share price plunge…

March 31, 2010 By Lawyers Weekly
expand image

Slater & Gordon has announced it is conducting a detailed investigation into shock disclosures made by Australian company Sigma Pharmaceuticals which resulted in a massive share price plunge today.

Senior litigator Ben Phi said he is not surprised that shareholders feel aggrieved as a result of the share price plunge which followed Sigma's announcement that it experienced a loss of $385 million for the 2010 financial year, with a net profit 26.5 per cent below market expectations.

"The company has disclosed a cash flow crisis caused by increased competition and margin pressures in its Generics business," said Phi.

"The goodwill impairments announced by Sigma relate to aggressive competition in the Generics market, and Pharmaceuticals Benefit Scheme reforms, which have been known to Sigma for some time."

Phi confirmed that Slater & Gordon is investigating whether the company have misled shareholders by breaching their obligations of continuous disclosure, and whether it had a "reasonable basis for its September profit guidance".

"We are particularly concerned with whether Sigma's disclosures have been appropriate, both in terms of what has been said to the market and what has not been disclosed, particularly given that $300m in capital was raised in September 2009," he said.

You need to be a member to post comments. Become a member today
Got a tip for us?
If you have any news tips or stories to share, feel free to send them our way.
Momentum Media Logo
Most Innovative Company